HAF017). A specific band was detected for ST2/IL-33 R at approximately 50 kDa (as indicated). This experiment was conducted under reducing conditions and using Immunoblot Buffer Group 1." alt="Western blot shows lysates of human kidney tissue and human lung tissue. PVDF membrane was probed with 0.2 µg/mL of Goat Anti-Human ST2/IL-33 R Antigen Affinity-purified Polyclonal Antibody (Catalog # AF523) followed by HRP-conjugated Anti-Goat IgG Secondary Antibody (HAF017). A specific band was detected for ST2/IL-33 R at approximately 50 kDa (as indicated). This experiment was conducted under reducing conditions and using Immunoblot Buffer Group 1." class="big_thumb" />
| Formulation | Catalog # | Availability | Price | |
|---|---|---|---|---|
| Carrier Free | AF523-SP | |||
3625-IL) induces proliferation in the D10.G4.1 mouse helper T cell line in a dose-dependent manner (orange line), as measured by Resazurin (Catalog # AR002). Under these conditions, proliferation elicited by IL-33 is neutralized (green line) by increasing concentrations of Goat Anti-Mouse ST2/IL-33 R Antigen Affinity-purified Polyclonal Antibody (Catalog # AF1004). The ND50 is typically 1-6 µg/mL." alt="Recombinant Human IL-33 (Catalog # 3625-IL) induces proliferation in the D10.G4.1 mouse helper T cell line in a dose-dependent manner (orange line), as measured by Resazurin (Catalog # AR002). Under these conditions, proliferation elicited by IL-33 is neutralized (green line) by increasing concentrations of Goat Anti-Mouse ST2/IL-33 R Antigen Affinity-purified Polyclonal Antibody (Catalog # AF1004). The ND50 is typically 1-6 µg/mL." class="big_thumb" />
| Formulation | Catalog # | Availability | Price | |
|---|---|---|---|---|
| Carrier Free | AF1004-SP | |||
MAB0061, open histogram), followed by Allophycocyanin-conjugated Anti-Rat IgG F(ab')2Secondary Antibody (Catalog # F0113)." alt="P815 mouse mastocytoma cell line was stained with Rat Anti-Mouse ST2/IL-33 R Monoclonal Antibody (Catalog # MAB10041, filled histogram) or isotype control antibody (Catalog # MAB0061, open histogram), followed by Allophycocyanin-conjugated Anti-Rat IgG F(ab')2Secondary Antibody (Catalog # F0113)." class="big_thumb" />
| Formulation | Catalog # | Availability | Price | |
|---|---|---|---|---|
| BSA Free | NBP1-85251-25ul | |||
219-IL) in a dose-dependent manner (orange line), as measured by the Human IFN-gamma Quantikine ELISA Kit (Catalog # DIF50C). Under these conditions, IFN-gamma secretion elicited by IL-33 is neutralized (green line) by increasing concentrations of Mouse Anti-Human/Primate ST2/IL-33 R Monoclonal Antibody (Catalog # MAB523). The ND50 is typically 0.3-1.5 µg/mL." alt="Recombinant Human IL-33 induces IFN-gamma secretion in Human Peripheral Blood Mononuclear cells (PBMC) in the presence of Recombinant Human IL-12 (Catalog # 219-IL) in a dose-dependent manner (orange line), as measured by the Human IFN-gamma Quantikine ELISA Kit (Catalog # DIF50C). Under these conditions, IFN-gamma secretion elicited by IL-33 is neutralized (green line) by increasing concentrations of Mouse Anti-Human/Primate ST2/IL-33 R Monoclonal Antibody (Catalog # MAB523). The ND50 is typically 0.3-1.5 µg/mL." class="big_thumb" />
| Formulation | Catalog # | Availability | Price | |
|---|---|---|---|---|
| Carrier Free | MAB523-SP | |||
| Carrier Free | MAB523-500 | |||
![N/A ST2/IL-33R [Biotin]](http://images.novusbio.com/fullsize/elisa/DATA_ST2_DY523_ELISA_2475.jpg "N/A ST2/IL-33R [Biotin]")
![N/A ST2/IL-33R [Biotin]](http://images.novusbio.com/fullsize/elisa/DATA_ST2_DY523_ELISA_2088.jpg)
![N/A ST2/IL-33R [HRP]](http://images.novusbio.com/fullsize/elisa/DATA_ST2_DST200_ELISA_832.jpg "N/A ST2/IL-33R [HRP]")
![N/A ST2/IL-33R [HRP]](http://images.novusbio.com/fullsize/elisa/ST2_DST200_ELISA_186.jpg)
VC004). Before incubation with the primary antibody, tissue was subjected to heat-induced epitope retrieval using Antigen Retrieval Reagent-Basic (
HAF109). This experiment was conducted under reducing conditions and using the 12-230 kDa separation system." class="big_thumb" />
219-IL) in a dose-dependent manner (orange line), as measured by the Human IFN-gamma Quantikine ELISA Kit (
1004-MR) was serially diluted and captured by Rat Anti-Mouse ST2/IL-33R Monoclonal Antibody (Catalog # 
AR002). Under these conditions, proliferation elicited by IL-33 is neutralized (green line) by increasing concentrations of Rat Anti-Mouse ST2/IL-33 R Monoclonal Antibody (Catalog # MAB10041). The ND50 is typically 0.5-3 µg/mL." class="big_thumb" />
1004-MR) was serially diluted and captured by Rat Anti-Mouse ST2/IL-33R Monoclonal Antibody (Catalog # MAB10041) coated on a Clear Polystyrene Microplate (Catalog # ![Western Blot: ST2/IL-33 R Antibody [NBP1-85251] - Analysis in human cell line HEL.](http://images.novusbio.com/fullsize/ST2-IL-33-R-Antibody-Western-Blot-NBP1-85251-img0008.jpg "Western Blot: ST2/IL-33 R Antibody [NBP1-85251] - Analysis in human cell line HEL.")
![Immunohistochemistry-Paraffin: ST2/IL-33 R Antibody [NBP1-85251] - Staining of human placenta shows moderate membranous positivity in trophoblastic cells.](http://images.novusbio.com/fullsize/ST2-IL-33-R-Antibody-Immunohistochemistry-Paraffin-NBP1-85251-img0007.jpg)
![Immunohistochemistry-Paraffin: ST2/IL-33 R Antibody [NBP1-85251] - Staining of human stomach shows moderate membranous positivity in glandular cells.](http://images.novusbio.com/fullsize/ST2-IL-33-R-Antibody-Immunohistochemistry-Paraffin-NBP1-85251-img0004.jpg)
![Immunohistochemistry-Paraffin: ST2/IL-33 R Antibody [NBP1-85251] - Staining of human kidney shows moderate membranous positivity in cells in glomeruli.](http://images.novusbio.com/fullsize/ST2-IL-33-R-Antibody-Immunohistochemistry-Paraffin-NBP1-85251-img0005.jpg)
![Immunohistochemistry-Paraffin: ST2/IL-33 R Antibody [NBP1-85251] - Staining of human lung shows moderate membranous positivity in pneumocytes.](http://images.novusbio.com/fullsize/ST2-IL-33-R-Antibody-Immunohistochemistry-Paraffin-NBP1-85251-img0006.jpg)
![N/A ST2/IL-33R [HRP]](http://images.novusbio.com/fullsize/elisa/DATA_ST2_MST200_ELISA_1035.jpg "N/A ST2/IL-33R [HRP]")
![N/A ST2/IL-33R [HRP]](http://images.novusbio.com/fullsize/elisa/ST2_MST200_ELISA_325.jpg)
![Immunocytochemistry/ Immunofluorescence: ST2/IL-33R Antibody [NBP2-53096] - ST2 mediates the IL-33 response on IA. A, Detection of ST2 transcripts in mouse DRGs. Neither the reverse-transcription negative control (without reverse transcriptase, -RT) nor nontemplate negative control (-H2O) showed a signal. B, Immunoblot analysis of ST2 protein abundance in mouse DRGs. Blots are representative of three independent experiments with beta -tubulin serving as a loading control. C, Colabeling (white arrows) of ST2 & NeuN, GS, CGRP, IB4 & NF200 in mouse DRG sections. Pre-incubation of ST2 antibody with excessive ST2 blocking peptide served as the specificity control of ST2 antibody. Scale bar, 50 µm. D, Time course of IA changes (left) & bar graph (right) demonstrating that pretreating DRG neurons with an ST2 neutralizing antibody (ST2 Ab, 2 µg/mL) prevented the IL-33-induced IA decrease (n = 9 cells). The application of 2 µg/mL ST2 Ab alone did not affect IA (n = 7 cells). Arabic numerals indicate the points utilized for example current traces. **p < 0.01 vs. IL-33 without ST2 Ab, paired t test. E, Immunoblot analysis of ST2 protein abundance in the control siRNA (NC-siRNA) & ST2 siRNA-treated (ST2-siRNA) groups. Blots are representative of three independent experiments with beta -tubulin serving as a loading control. **p < 0.01 vs. NC-siRNA, unpaired t test. F, Bar graph indicating that treatment with ST2-siRNA (n = 12 cells), but not NC-siRNA (n = 11 cells), abrogated the 50 ng/mL IL-33-induced IA decrease. *p < 0.05 vs. control + NC-siRNA, one-way ANOVA with a Bonferroni post hoc test. Image collected & cropped by CiteAb from the following publication (//pubmed.ncbi.nlm.nih.gov/35265208), licensed under a CC-BY license. Not internally tested by Novus Biologicals.](http://images.novusbio.com/fullsize/nbp2-53096_rabbit-polyclonal-st2-il-33r-antibody-31020241611354.jpg "Immunocytochemistry/ Immunofluorescence: ST2/IL-33R Antibody [NBP2-53096] - ST2 mediates the IL-33 response on IA. A, Detection of ST2 transcripts in mouse DRGs. Neither the reverse-transcription negative control (without reverse transcriptase, -RT) nor nontemplate negative control (-H2O) showed a signal. B, Immunoblot analysis of ST2 protein abundance in mouse DRGs. Blots are representative of three independent experiments with beta -tubulin serving as a loading control. C, Colabeling (white arrows) of ST2 & NeuN, GS, CGRP, IB4 & NF200 in mouse DRG sections. Pre-incubation of ST2 antibody with excessive ST2 blocking peptide served as the specificity control of ST2 antibody. Scale bar, 50 µm. D, Time course of IA changes (left) & bar graph (right) demonstrating that pretreating DRG neurons with an ST2 neutralizing antibody (ST2 Ab, 2 µg/mL) prevented the IL-33-induced IA decrease (n = 9 cells). The application of 2 µg/mL ST2 Ab alone did not affect IA (n = 7 cells). Arabic numerals indicate the points utilized for example current traces. **p < 0.01 vs. IL-33 without ST2 Ab, paired t test. E, Immunoblot analysis of ST2 protein abundance in the control siRNA (NC-siRNA) & ST2 siRNA-treated (ST2-siRNA) groups. Blots are representative of three independent experiments with beta -tubulin serving as a loading control. **p < 0.01 vs. NC-siRNA, unpaired t test. F, Bar graph indicating that treatment with ST2-siRNA (n = 12 cells), but not NC-siRNA (n = 11 cells), abrogated the 50 ng/mL IL-33-induced IA decrease. *p < 0.05 vs. control + NC-siRNA, one-way ANOVA with a Bonferroni post hoc test. Image collected & cropped by CiteAb from the following publication (//pubmed.ncbi.nlm.nih.gov/35265208), licensed under a CC-BY license. Not internally tested by Novus Biologicals.")
![Western Blot: ST2/IL-33R Antibody [NBP2-53096] - ST2 mediates the IL-33 response on IA. A, Detection of ST2 transcripts in mouse DRGs. Neither the reverse-transcription negative control (without reverse transcriptase, -RT) nor nontemplate negative control (-H2O) showed a signal. B, Immunoblot analysis of ST2 protein abundance in mouse DRGs. Blots are representative of three independent experiments with beta -tubulin serving as a loading control. C, Colabeling (white arrows) of ST2 & NeuN, GS, CGRP, IB4 & NF200 in mouse DRG sections. Pre-incubation of ST2 antibody with excessive ST2 blocking peptide served as the specificity control of ST2 antibody. Scale bar, 50 µm. D, Time course of IA changes (left) & bar graph (right) demonstrating that pretreating DRG neurons with an ST2 neutralizing antibody (ST2 Ab, 2 µg/mL) prevented the IL-33-induced IA decrease (n = 9 cells). The application of 2 µg/mL ST2 Ab alone did not affect IA (n = 7 cells). Arabic numerals indicate the points utilized for example current traces. **p < 0.01 vs. IL-33 without ST2 Ab, paired t test. E, Immunoblot analysis of ST2 protein abundance in the control siRNA (NC-siRNA) & ST2 siRNA-treated (ST2-siRNA) groups. Blots are representative of three independent experiments with beta -tubulin serving as a loading control. **p < 0.01 vs. NC-siRNA, unpaired t test. F, Bar graph indicating that treatment with ST2-siRNA (n = 12 cells), but not NC-siRNA (n = 11 cells), abrogated the 50 ng/mL IL-33-induced IA decrease. *p < 0.05 vs. control + NC-siRNA, one-way ANOVA with a Bonferroni post hoc test. Image collected & cropped by CiteAb from the following publication (//pubmed.ncbi.nlm.nih.gov/35265208), licensed under a CC-BY license. Not internally tested by Novus Biologicals.](http://images.novusbio.com/fullsize/nbp2-53096_rabbit-polyclonal-st2-il-33r-antibody-310202416114743.jpg)
![Western Blot: ST2/IL-33R Antibody [NBP2-53096] - p38 beta mediates the IL-33-induced IA decrease. A, immunoblot analysis of p38 alpha & p38 beta protein abundance in DRGs. Mouse brains were used as positive controls. Blots are representative of three independent experiments with beta -tubulin serving as a loading control. B, time course of IA changes (left) & bar graph (right) indicating the effect of 50 ng/mL IL-33 on IA in the presence of JX-401 (50 nM, n = 8 cells). The application of 50 nM JX-401 (n = 6 cells) alone had no significant effect on IA. Arabic numerals indicate the points utilized for the example current traces. C, immunoblot analysis showing that the protein expression level of p38 beta was significantly reduced in the p38 beta -siRNA-treated groups, while the expression of p38 alpha was not affected. Blots are representative of three independent experiments with beta -tubulin serving as a loading control. **p < 0.01 vs. NC-siRNA, unpaired t test. D, example traces (left) & bar graph (right) demonstrating the effects of 50 ng/mL IL-33 on IA in cells treated with control siRNA (NC-siRNA, n = 9 cells) or p38 beta -siRNA (n = 11 cells). **p < 0.01 vs. control + NC-siRNA group, one-way ANOVA with a Bonferroni post hoc test. Image collected & cropped by CiteAb from the following publication (//pubmed.ncbi.nlm.nih.gov/35265208), licensed under a CC-BY license. Not internally tested by Novus Biologicals.](http://images.novusbio.com/fullsize/nbp2-53096_rabbit-polyclonal-st2-il-33r-antibody-310202416121979.jpg)
![Western Blot: ST2/IL-33R Antibody [NBP2-53096] - ST2 mediates the IL-33 response on IA. A, Detection of ST2 transcripts in mouse DRGs. Neither the reverse-transcription negative control (without reverse transcriptase, -RT) nor nontemplate negative control (-H2O) showed a signal. B, Immunoblot analysis of ST2 protein abundance in mouse DRGs. Blots are representative of three independent experiments with beta -tubulin serving as a loading control. C, Colabeling (white arrows) of ST2 & NeuN, GS, CGRP, IB4 & NF200 in mouse DRG sections. Pre-incubation of ST2 antibody with excessive ST2 blocking peptide served as the specificity control of ST2 antibody. Scale bar, 50 µm. D, Time course of IA changes (left) & bar graph (right) demonstrating that pretreating DRG neurons with an ST2 neutralizing antibody (ST2 Ab, 2 µg/mL) prevented the IL-33-induced IA decrease (n = 9 cells). The application of 2 µg/mL ST2 Ab alone did not affect IA (n = 7 cells). Arabic numerals indicate the points utilized for example current traces. **p < 0.01 vs. IL-33 without ST2 Ab, paired t test. E, Immunoblot analysis of ST2 protein abundance in the control siRNA (NC-siRNA) & ST2 siRNA-treated (ST2-siRNA) groups. Blots are representative of three independent experiments with beta -tubulin serving as a loading control. **p < 0.01 vs. NC-siRNA, unpaired t test. F, Bar graph indicating that treatment with ST2-siRNA (n = 12 cells), but not NC-siRNA (n = 11 cells), abrogated the 50 ng/mL IL-33-induced IA decrease. *p < 0.05 vs. control + NC-siRNA, one-way ANOVA with a Bonferroni post hoc test. Image collected & cropped by CiteAb from the following publication (//pubmed.ncbi.nlm.nih.gov/35265208), licensed under a CC-BY license. Not internally tested by Novus Biologicals.](http://images.novusbio.com/fullsize/nbp2-53096_rabbit-polyclonal-st2-il-33r-antibody-31020241613611.jpg)
![Immunocytochemistry/ Immunofluorescence: ST2/IL-33R Antibody [NBP2-53096] - The IL-33-induced IA decrease requires Syk. A, effects of 50 ng/mL IL-33 on protein abundance of phospho-JAK2 (p-JAK2)/total JAK2 (t-JAK2). Blots are representative of three independent experiments w/ beta -tubulin serving as a loading control. B, colabeling (white arrows) of ST2 & JAK2 & Syk in mouse DRG sections. Scale bar, 50 µm. C, time course of IA changes (left) & bar graph (right) showing that pretreatment of DRG neurons w/ AG490 (10 µM) did not affect IL-33-induced IA response (n = 8 cells). Application of 10 µM AG490 alone did not affect IA (n = 7 cells). Arabic numerals indicate points utilized for example current traces. D, effects of 50 ng/mL IL-33 on p-Syk protein abundance in presence/absence of ST2 neutralizing antibody (ST2 Ab, 2 µg/mL) in DRG cells. Blots are representative of three independent experiments w/ beta -tubulin serving as a loading control. **p < 0.01 vs. control, unpaired t test. E-G, time course of IA changes showing that pretreating DRG neurons w/ R406/GS9973, but not KT-5720, prevented IL-33-induced IA response. Arabic numerals indicate points utilized for example current traces. H, bar graph showing effect of 50 ng/mL IL-33 on IA in cells pretreated w/ R406 (1 µM, n = 11 cells), GS9973 (10 µM, n = 8 cells), & KT-5720 (1 µM, n = 9 cells). Application of 1 µM R406 (n = 7 cells), 10 µM GS9973 (n = 6 cells)/1 µM KT-5720 (n = 7 cells) alone had no significant effect on IA. **p < 0.01 vs. control, paired t test. I, colabeling (white arrows) of ST2 & PKA in mouse DRG sections. Scale bar, 50 µm. J, bar graph demonstrating effect of 20 µM forskolin on IA in presence (n = 7 cells)/absence (n = 5 cells) of KT-5720 (1 µM). ***p < 0.001 vs. forskolin w/out KT-5720, paired t test. Image collected & cropped by CiteAb from following publication (//pubmed.ncbi.nlm.nih.gov/35265208), licensed under a CC-BY license. Not internally tested by Novus Biologicals.](http://images.novusbio.com/fullsize/nbp2-53096_rabbit-polyclonal-st2-il-33r-antibody-310202416114719.jpg)
![Rat tissue extract (50 ug) was separated by 7.5% SDS-PAGE, and the membrane was blotted with ST2 antibody [N1C1] (NBP2-53096) diluted at 1:1000. The HRP-conjugated anti-rabbit IgG antibody was used to detect the primary antibody.](http://images.novusbio.com/fullsize/nbp2-53096_rabbit-polyclonal-st2-il-33r-antibody-western-blot-261120251962712.jpg)
![Whole cell extract (30 ug) was separated by 10% SDS-PAGE, and the membrane was blotted with ST2 antibody [N1C1] (NBP2-53096) diluted at 1:500.](http://images.novusbio.com/fullsize/nbp2-53096_rabbit-polyclonal-st2-il-33r-antibody-western-blot-261120251828109.jpg)
![Rat tissue extract (50 ug) was separated by 10% SDS-PAGE, and the membrane was blotted with ST2 antibody [N1C1] (NBP2-53096) diluted at 1:500.](http://images.novusbio.com/fullsize/nbp2-53096_rabbit-polyclonal-st2-il-33r-antibody-western-blot-2611202518283518.jpg)
